newsfilter
← Latest News
Business Wire·

Stoke Therapeutics to Present at the Cantor Global Healthcare Conference

  • Stoke Therapeutics (NASDAQ: STOK) announced that CEO Ian F. Smith & Chief Patient Officer Jason Hoitt will present at the Cantor Global Healthcare Conference on September 9, 2026 at 1:00 p.m. ET.
  • A live webcast & archived replay of the presentation will be available in the Investors & News section of Stoke's website.
  • Stoke utilizes its proprietary TANGO approach to develop antisense oligonucleotides that restore protein levels in diseases caused by haploinsufficiency.
  • Lead investigational medicine zorevunersen is currently in a Phase 3 study for Dravet syndrome & has demonstrated potential for disease modification.
  • Zorevunersen aims to increase functional NaV1.1 protein production from the wild-type SCN1A gene to reduce seizure frequency & improve neurodevelopment.
  • Zorevunersen holds orphan drug designations from the FDA & EMA, rare pediatric disease & Breakthrough Therapy designations from the FDA, & a Breakthrough Therapy designation from China's Center for Drug Evaluation.
  • A strategic collaboration exists between Stoke & Biogen (NASDAQ: BIIB) where Stoke retains exclusive rights in the US, Canada, & Mexico while Biogen holds rest-of-world rights.
  • Zorevunersen remains investigational with safety & efficacy not yet evaluated by any regulatory authority.